Abstract
Metronidazole (MTNZ) is an antiprotozoa drug, could be labeled with the 99mTc. MTZL could be used as an ideal vehicle to deliver radioactive decay energy of 99mTc to the sites of tumor, thus facilitate tumor imaging. The process of labeling was done using tin chloride as reducing agent. The optimum conditions required to label 25 μg MTZL were 100 μg stannous chloride, 30 min reaction time, room temperature at pH 7–9 using 0.5 M phosphate buffer. The radiochemical purity of the labeled compound, at the above conditions, was determined using paper chromatography. The yield was about 93%. About 2.5 × l06 of Ehrlich Ascites Carcinoma (EAC) was injected intrapritoneally (i.p) to produce ascites and intramuscularly (i.m) in the right thigh to produce solid tumor in female mice. Biodistribution studies were carried out by injecting solution of 99mTc-MTZL in normal and tumor bearing mice. The uptake in ascites was over 5% of the injected dose per gram tissue body weight, at 4 h post injection and above 4% in solid tumor. These data revealed localization of the tracer in the tumor tissues with high percentage sufficient to use 99 mTc MTZL as promising tool for diagnosis of tumor.
Similar content being viewed by others
References
Roelvid TA, Horenblas S, Moonen LM, Te Velde A, Meinhardt W, Bartilink H (1997) Ned Tijdschr Geneskd 3:171
Boyd RE (1997) Appl Radiat Isot 48:1027
Molinski V (1982) Int J Appl Radiat Isot 33:811
Davison A (1983) The coordination chemistry of technetium, Cortina International. Verona, Italy, pp 3–14
Robbins PJ (1984) Chromatography of technetium-99m radiopharmaceuticals a practical guide. Society of Nuclear Medicine, New York, p 51
Motaleb MA (2001) Ph.D. Thesis, Faculty of Science, Ain-Shams University, p 25
Boyd RE (1986) J Nucl Spectrum Aust 2(1):18
El-Kolaly MT, Talaat H, Botros N (1996) Proceedings of the sixth conference of nuclear sciences and applications, vol 3. Egypt, p 124
Delgado JN, Remers WA (eds) (1992) Wilson and Gisvold’s textbook of organic and pharmaceutical chemistry, 9th edn., JB Lippincott Company, Philadelphia, p 313
Martindale W (2001) In: The extra pharmacopoeia, 29th edn., Pharmaceutical Press, London, p 658
Svoboda K, Lezama J, Melichor F (1985) J Radioanal Nucl Chem Lett 96:405
El-Kolaly MT (1993) J Radioanal Nucl Chem Lett 170:293
Johannsen B, Spies H (1991) In: Workshop on generator and cyclotron produced radiopharmaceuticals, Riyad, Saudi Arabia, 13–31 October 1991
Abd El-Ghany E (1998) M.Sc. Thesis, Faculty of Pharmacy, Cairo University, p 71
Meares CF, Goodwin DA (1984) J Pro Chem 3(2):215
Subramanian G, Mcafee JG, Blair RJ (1975) J Nucl Med 16:744
Mock B, English D (1987) J Nucl Med 28:1471
Subramanian G, McAfee J (1971) Radiology 98:192
El-Asrag H, El-Kolaly M, El-Sayed AA, Abd El-Bary A (1995) J Radioanal Nucl Chem 196(1):45
Korde A, Venkatesh M (1998) In: International symposium on modem trends in radiopharmaceuticals for diagnosis and therapy, vol 30, IAEA, Lisbon, Portugal, 3 April 1998, SM-355/13
Dupertuis Y, Buchegger F, Pichard C (2003) Cancer Biother Radiopharm 18(1):7
Guzman FM, Archundia LVD, Cortés SH (2008) J Braz Chem Soc 19(3):380
Proulx A, Ballinger J, Galenchyn Y (1989) Int J Rad Appl Instrum A 40:95
Ballinger RJ (2001) Semin Nucl Med 31(4):321
Kenji Y, Hideo K, Kazuki F (1999) J Nucl Med 40:854
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ibrahim, I.T. Preparation of 99mTc-metronidazole as a model for tumor imaging. J Radioanal Nucl Chem 281, 669–674 (2009). https://doi.org/10.1007/s10967-009-0040-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-009-0040-8